Additional filters Number of results: 7
inhibitor
Alen Vrtarić, Nora Nikolac Gabaj, Ivana Ćelap
Short communications, Volume 34, October, Issue 3
KEYWORDS: preanalytical phase; glucose; glucose inhibitor; anticoagulants; citrate
https://doi.org/10.11613/BM.2024.030901
Sandra Margetić, Ivana Ćelap, Diana Delić Brkljačić, Nikola Pavlović, Sandra Šupraha Goreta, Ivana Kobasić, Arijana Lovrenčić-Huzjan, Vanja Bašić Kes
Original Articles, Volume 30, February, Issue 1
KEYWORDS: apixaban; DOAC; factor Xa inhibitors; LMWH; rivaroxaban
https://doi.org/10.11613/BM.2020.010702
Benjamin Lopez, Nicolas Bertier, Emmanuel Ledoult, Romane Joudinaud, Mehdi Maanaoui, Victoria Majerus, Emmanuelle Moitrot, Anne-Sophie Deleplancque, Stéphanie Rogeau, David Launay, Guillaume Lefèvre, Myriam Labalette, Sylvain Dubucquoi
Original Articles, Volume 29, October, Issue 3
KEYWORDS: reference values; complement C3c; complement C4; classical complement pathway; complement C1 inhibitor protein
https://doi.org/10.11613/BM.2019.030707
Franz Ratzinger, Tanja Panic, Helmuth Haslacher, Thomas Perkmann, Klaus G. Schmetterer, Sabine Belik, Georg Maenner, Ingrid Pabinger, Peter Quehenberger
Original Papers, Volume 27, October, Issue 3
KEYWORDS: blood coagulation; blood coagulation tests; lupus coagulation inhibitor; partial thromboplastin time
https://doi.org/10.11613/BM.2017.030705
Saša Anžej Doma, Andreas Hillarp, Tadej Pajič, Dušan Andoljšek, Peter Černelč, Irena Preldžnik Zupan
Case Report, Volume 26, June, Issue 2
KEYWORDS: inhibitor; autoantibody; blood coagulation factor; enzyme-linked immunosorbent assay
https://doi.org/10.11613/BM.2016.033
Xi Zhang, Goce Dimeski, Chamindie Punyadeera
Original papers, Volume 24, June, Issue 2
KEYWORDS: plasminogen activator inhibitor 1; saliva; immunoassay; cardiovascular diseases; analytical validation
https://doi.org/10.11613/BM.2014.028
Zrinka Alfirevic, Ana-Maria Simundic, Nora Nikolac, Nikola Sobocan, Igor Alfirevic, Mario Stefanovic, Zeljko Vucicevic, Elizabeta Topic
Original papers, Volume 20, June, Issue 2
KEYWORDS: thrombophilia; coagulation disorders; polymorphism; FV Leiden; factor II; plasminogen activator inhibitor-1; methylenetetrahydrofolate reductase
https://doi.org/10.11613/BM.2010.028